Lymphoma Specialists Lament the Discontinuation of Underprescribed Bexxar

The discontinuation of Bexxar, a radioimmunotherapy for B-cell lymphoma, by GlaxoSmithKline (GSK) was met with disappointment by oncology specialists who considered it an effective but under-prescribed treatment. Despite its ability to induce long-term remissions and its relatively mild side effects, Bexxar's use declined due to marketing issues, lack of focused development, and competition from other treatments like bendamustine. In 2012, fewer than 75 patients in the U.S. received Bexxar, leading to its discontinuation. GSK cited the availability of other treatment options and a continued decline in Bexxar's use as reasons for its decision. The company planned to make the cell line used to produce Bexxar's antibody available for research purposes, reflecting a commitment to transparency and collaboration.